Navigation Links
Study of Lacrisert(R) Dry Eye Insert Published in The Ocular Surface
Date:8/19/2009

LAWRENCEVILLE, N.J., Aug. 19 /PRNewswire/ -- Aton Pharma, Inc. announced today that The Ocular Surface, a leading peer-reviewed ophthalmology journal, has published an article that includes results of a retrospective case series study of dry eye patients using Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert). The article, "Extending the Duration of Tear Film Protection: Review and Retrospective Case Series Study of the Hydroxypropyl Cellulose Ophthalmic Insert," by Arden H. Wander, M.D. and Bruce H. Koffler, M.D., discusses how the duration of tear film protection in dry eye patients can be extended using artificial tear formulations with enhanced viscosity/polymeric systems, the hydroxypropyl cellulose insert and other approaches.

Lacrisert is a preservative-free, once-daily*, sustained release prescription insert indicated for moderate to severe dry eye, that helps to retain moisture, stabilize the tear film, and lubricate the eye.

"Our retrospective case series indicates that the hydroxypropyl cellulose ophthalmic insert can be a valuable treatment for dry eye patients, either alone or in conjunction with other therapies," concluded Dr. Koffler. "The reports of symptom improvement and extremely low rate (2.5%) of adverse effects suggest that the inserts are an appropriate long-term therapy. The fact that so many patients had been using the inserts for more than 5 years suggests that it is a relatively safe, tolerable, and effective therapy."

"This is the first peer-review publication for Lacrisert in more than two decades," stated Michael G. Wells, Chief Executive Officer of Aton Pharma. "Pursuing scientific and clinical publications is part of our commitment to contributing to physician knowledge of Lacrisert."

Recently, results of a large (n = 520) multi-center patient registry study of the Lacrisert insert were presented during
'/>"/>

SOURCE Aton Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ... focused on the development of oral drug delivery ... its Phase IIa clinical trial of ORMD-0801, the ... 1 diabetes. The trial was conducted in ... Food and Drug Administration (FDA) Investigational New Drug ...
(Date:10/22/2014)...   Surefire Medical , Inc., the developer of ... targeted delivery of embolization agents in minimally invasive direct-to-tumor ... John R. Daniels , MD of the University of ... Steven C. Katz , MD of the Roger ... Board (SAB).    "The role of the ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... and dermatology therapies. PV-10, its novel investigational drug for ... the potential for systemic side effects. Its oncology focus ... liver. Provectus has completed phase 2 trials of PV-10 ... as a topical treatment for atopic dermatitis and psoriasis. ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
... Patent Covers Compositions and Methods, ROCKVILLE, Md., ... a clinical-stage pharmaceutical company developing,therapeutics for the treatment ... of U.S. Patent No. 7,371,741 covering analogs of ... of use intellectual property protection through 2025 for ...
... BASEL, Switzerland, June 11 , - Data ... That,NeoRecormon use has no Negative Impact on Overall ... all 12 prospective, randomised, controlled,studies in 2,301 cancer ... has no negative impact on survival, tumour,progression or ...
Cached Medicine Technology:EntreMed Receives New Patent for 2-Methoxyestradiol Analogs 2EntreMed Receives New Patent for 2-Methoxyestradiol Analogs 3New Meta-Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients 2
(Date:10/22/2014)... only 24 hours in a day, that doesn’t seem to be ... their busy schedules for exercise and fitness. Fortunately, one does not ... shape. Here are five ways you can reach your fitness and ... Commute , Consider riding a bike or taking the bus or ... If you must use your car to get to work, start ...
(Date:10/22/2014)... MA (PRWEB) October 22, 2014 ... new solutions for the treatment of bacterial infections, microbial ... Sinskey has joined its board of directors. , ... and Engineering Systems at The Massachusetts Institute of Technology, ... MIT faculty since 1968. Dr. Sinskey also holds positions ...
(Date:10/22/2014)... -- Two sisters in high school have developed ways ... Medha Krishen use electronic stethoscopes, which electronically amplify body ... patterns or heartbeats. Ilina, a senior at Port ... a way to detect early lung damage in people ... Ilina recorded one breath cycle each from 16 smokers, ...
(Date:10/22/2014)... 2014 (HealthDay News) -- Measures taken by Firestone officials ... Liberia may have limited the spread of the disease ... The Firestone Natural Rubber Co. provides health services to ... nearby densely populated communities. Between Aug. 1 and ... cases among those 80,000 people. That incidence rate of ...
(Date:10/20/2014)... The newly updated Worldwide Medical Market Forecasts ... facts, figures and forecasts on the global medical markets. ... categories the Worldwide Medical Market Forecasts to 2019 ... on the worldwide medical market to reveal key insights ... data for 2010-2019, covering each country market individually, allowing ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4
... Cornell University in the United States used rich microdata ... to analyze the correlation between high school completion and ... and obesity. Their findings, which are to be ... Journal of Labor Economics, reveal that, high ...
... cloned a cow with genes resistant to mad cow disease. ... a 55-kg calf //in the eastern province of Shandong ... to have used gene-transplant technology to introduce the genes to ... ,The lead researchers were Dong Yajuan and Bo Xuejin ...
... role in regulating cell death, a Queen’s University study has ... may be used to promote cell death in cancer cells ... as in neuronal cells in the case of Alzheimer’s or ... Molecular Medicine with the Cancer Biology and Genetics division of ...
... implemented by government are needed to improve mental health in ... Australia is in need of a new nationalwise approach with ... ,A report on the Time for Service says mental health ... following 5 years was being made. ,It added, ...
... Center have successfully accomplished the removal of an extremely rare, ... ,They removed one of his two left arms that ... left arm is further up his shoulder. ,‘We ... formed just as they would be for a normal arm,’ ...
... out human-to-human transmission of bird flu in the case ... // , easing fears that the virus might be ... ,'The negative test results for all four nurses ... efficiently or sustainably among humans at present,' WHO said ...
Cached Medicine News:Health News:Protein’s role in regulating cell death sets direction for Alzheimer’s, Parkinson’s and cancer resea 2
... Farnsworth Dichotomous testing sets are designed to ... Farnsworth D15 test is used to separate ... The L'Anthony Desaturated test is much more ... deficiency from Normal. Both of these ...
... The NOW Strep A test is as easy ... minutes to results. Increase patient satisfaction with rapid ... can treat your patient immediately with the appropriate ... , ,Intended Use: ,The NOW® Strep A Test ...
12 mm single use, reloadable laparoscopic linear stapler with titanium staples....
Single Use Loading Units with Titanium Staples for use with Powered MULTIFIRE ENDO GIA™ 60 (15 mm Single Use Stapler with Titanium Staples)....
Medicine Products: